These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy and safety of nitrous oxide for patients with treatment-resistant depression, a randomized controlled trial. Yan D; Liu B; Wei X; Ou W; Liao M; Ji S; Peng Y; Liu J; Wu S; Wang M; Ju Y; Zhang L; Li Z; Li L; Zhang Y Psychiatry Res; 2022 Nov; 317():114867. PubMed ID: 36191556 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061 [TBL] [Abstract][Full Text] [Related]
5. Nitrous Oxide: an emerging novel treatment for treatment-resistant depression. Quach DF; de Leon VC; Conway CR J Neurol Sci; 2022 Mar; 434():120092. PubMed ID: 34953347 [TBL] [Abstract][Full Text] [Related]
6. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095 [TBL] [Abstract][Full Text] [Related]
8. Brain function changes reveal rapid antidepressant effects of nitrous oxide for treatment-resistant depression:Evidence from task-state EEG. Shao X; Yan D; Kong W; Sun S; Liao M; Ou W; Zhang Y; Zheng F; Li X; Li L; Hu B Psychiatry Res; 2023 Apr; 322():115072. PubMed ID: 36791487 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
10. Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: A systematic review and meta-analysis nitrous oxide in depressive disorders. Rech P; Custodio RM; Rodrigues Uggioni ML; Silveira Prestes G; Marçal F; Silveira VP; Dagostin VS; Colonetti T; Rosa MI Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110869. PubMed ID: 37813146 [TBL] [Abstract][Full Text] [Related]
11. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121 [TBL] [Abstract][Full Text] [Related]
13. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301 [TBL] [Abstract][Full Text] [Related]
14. Novel Augmentation Strategies in Major Depression. Martiny K Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173 [TBL] [Abstract][Full Text] [Related]
15. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355 [TBL] [Abstract][Full Text] [Related]
16. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study. Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635 [TBL] [Abstract][Full Text] [Related]
17. Empirical evidence for the neurocognitive effect of nitrous oxide as an adjunctive therapy in patients with treatment resistant depression: A randomized controlled study. Liu J; Zhao X; Wei X; Yan D; Ou W; Liao M; Ji S; Peng Y; Wu S; Wang M; Ju Y; Zhang L; Li Z; Liu B; Li L; Zhang Y Psychiatry Res; 2023 Aug; 326():115326. PubMed ID: 37390601 [TBL] [Abstract][Full Text] [Related]
20. Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales. Luckenbaugh DA; Ameli R; Brutsche NE; Zarate CA J Psychiatr Res; 2015 Feb; 61():40-5. PubMed ID: 25592045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]